mk-0616
merck
[]
in phase 2 study mk-0616 - new oral pcsk9i reduced ldl cholesterol by around 60% among people taking 30 mg or 18 mg daily, compared to those taking a placebo. #acc23 #acc2023 
Consultant Cardiology Pharm, A Professor,NICE HF Guidelines, ESC ACNAP, AAC, NHSE, UKCPA! Comments are my own.